TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00395304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate + montelukast
Description: Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate + montelukast
Description: Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate + montelukast
Description: Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate + montelukast
Description: Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate + salmeterol
Description: Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate + salmeterol
Description: Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
Study: NCT01449955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rapamycin
Description: Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotional memory reconsolidation. This is based on the fact that it inhibits the mammalian target of Rapamycin (mTOR) through directly binding the mTOR Complex1 (mTORC1). mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.~a single dosage of 15mg will be administered during this study.
Study: NCT02393248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Study: NCT00395304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate + salmeterol
Description: Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate + salmeterol
Description: Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate + salmeterol
Description: Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
Study: NCT02393248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Study: NCT00395304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate + salmeterol
Description: Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
Study: NCT01723488

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [F18] T808
Description: Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
Study: NCT01449955

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive
Study: NCT04348435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Hope Biosciences allogeneic adipose-derived mesenchymal stem cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
Study: NCT00386048

Intervention type: BEHAVIORAL
Intervention: Brief Cognitive-Behavioral Pain Management Training
Description: Participants complete a manualized, single session of training which includes: (A) education about the causes of sickle cell pain, (B) education about how the nervous system processes pain signals, and (C) explanations of how one can use cognitive and behavioral treatment (CBT) strategies to decrease the extent of pain experienced (all based on how the nervous system processes pain). Four specific CBT skills are taught and practiced by the participant (Progressive muscle relaxation, Controlled Deep Breathing, Imagery, and Distraction). The protocol explicitly emphasizes the use of CBT as a complimentary pain management tool to use in addition to the standard of care methods.
Study: NCT01519271

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exelon Patch (rivastigmine transdermal system)
Description: The Exelon Patch (rivastigmine transdermal system) is a Cholinesterase Inhibitor approved by the FDA to treat Alzheimer's and Parkinson's Disease Dementia.~5-10cm2 (4.6-9.5 mg of rivastigmine/24 hours )

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patches
Description: The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
Study: NCT01664546

Intervention type: PROCEDURE
Intervention: Trophectoderm biopsy
Study: NCT03556670

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Usual practice control
Study: NCT01555996

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early and Intensive Occupational Therapy
Description: Intervention group:Standard non-pharmacological prevention plus early and intensive OT. Begin in the first 24 hours in CCU admission. OT areas:1)Multi-sensory stimulation:Intense external stimulation, increase alertness,2)Positioning: Fixtures like dorxi-flexion splints, devices for preventing edema,etc,3)Cognitive Stimulation: Awareness, orientation, attention, memory, calculation, praxis and language,4)Training Activities of Daily Living (ADL): Keep a daily routine and independence in hygiene, grooming and feeding,5)Upper Limb Motor Stimulation (ULMS): Activate functional movement and strength ,6)Family involvement.~General Guidelines for intervention: Visit of an OT twice a day, 40 minutes each time, for 5 days; meeting of family training for promote strategies during the daily visit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard non-pharmacological delirium prevention
Description: Non-pharmacological strategies are the first line of approach in the prevention of delirium. It is recommended to implement some of these strategies, which are: Reorientation protocol, including information 4 times a day about time, date, place and reason for hospitalization; early mobilization by physical therapist 3 times a day, corrected sensory impairment (use such as eyeglasses, hearing aids); environment management, use clock and calendar in the patient´s room, promote supervision of a professional or family to avoid physical restraints; sleep protocol, like lower light, noise and nighttime drug administration and finally, reduction of any anticholinergic drugs and minimize the use of benzodiazepines.
Study: NCT01326143

Intervention type: DEVICE
Intervention: ORM Narval MRD
Study: NCT01948297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio1347 (CH5183284)
Description: Debio1347 (CH5183284) tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio1347 (CH5183284)
Description: Debio1347 (CH5183284) tablets for oral administration
Study: NCT00763620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: catheter for mini bronchoalveolar lavage
Description: For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.
Study: NCT02109783

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine 2mg
Description: Caffeine 2 mg versus 4 mg/kg or placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine 4 mg
Description: To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine 0
Description: To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
Study: NCT03715881

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral prednisolone administration 50 mg
Description: 50 mg oral prednisolone from the onset of the disease for 1 week, with the dose gradually reduced within 2 weeks and then discontinued
Study: NCT02217514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 high dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 high dose
Study: NCT01245400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Z-Lig
Description: ACL replacement

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: allograft
Description: ACL replacement
Study: NCT02966275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucagon-only bionic pancreas - glucagon
Description: A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Glucagon-only bionic pancreas - placebo
Description: A computer algorithm will automatically deliver placebo based on the signal from a minimally invasive continuous glucose monitor.
Study: NCT04348435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HB-adMSCs
Description: Hope Biosciences allogeneic adipose-derived mesenchymal stem cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Saline
Study: NCT01011088

Intervention type: OTHER
Description: Not any artificial interventions were given

Intervention type: OTHER
Description: Not any artificial interventions were given
Study: NCT02928666

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DSS for mitigating interactions between recommendations
Description: DSS that detects and mitigates interactions between recommendations, proposing a set of non-conflicting guideline recommendations
Study: NCT01804491

Intervention type: OTHER
Intervention: Motion Analysis
Description: 3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).

Intervention type: OTHER
Intervention: Motion Analysis
Description: 3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).

Intervention type: OTHER
Intervention: Motion Analysis
Description: 3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).

Intervention type: OTHER
Intervention: Motion Analysis
Description: 3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).

Intervention type: OTHER
Intervention: Motion Analysis
Description: 3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).

Intervention type: OTHER
Intervention: Motion Analysis
Description: 3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).

Intervention type: OTHER
Intervention: Motion Analysis
Description: 3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).
Study: NCT02393248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT04669691

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 antigen combined with MF59 adjuvant
Description: Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: H5N1 antigen combined with MF59 adjuvant
Description: Eligible subjects will be stratified by age at the time of enrollment into one of 2 age cohorts and within each age cohort will be randomly assigned (equally) to 1 of 6 study vaccine groups. Subjects in each study vaccine group will be scheduled to receive 2 injections of aH5N1 vaccine 3 weeks apart
Study: NCT03761589

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AFL Intervention
Description: The AFL intervention consisted of two 90-minute sessions per week for 12 months for both children and parents. The child physical activity sessions, held separately from the parent sessions, aimed to achieve 60 minutes of moderate-to-vigorous physical activity during each session through structured play activities, athletic drills, and sport exercises. Child dietary behaviors were taught through educational activities in small groups. For the parent program, behavior modification techniques were used to guide parents toward changing their own and their child's behavior. Take-home materials for self-monitoring of behaviors were used for both the child and the parent in order to reinforce concepts discussed in class.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Wait-List Control
Description: Families that were randomly assigned to the wait-list control group were asked not to change their normal physical activity or dietary behaviors for the duration of the 12-week waiting period. They were asked to participate in the baseline and 12-week evaluations and then they were enrolled to receive the 12-week intervention.
Study: NCT04148703

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Follow up post Pacemaker implantation in office
Description: All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by in-office follow-up

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow up post Pacemaker implantation by home monitoring
Description: All patients will be implanted with a single or dual chamber pacemaker according the implantation guidelines and will be followed by home monitoring
Study: NCT03730714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic, Epinephrine and Morphine
Description: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local Anesthetic, Epinephrine, Morphine and Surgicel
Description: Surgicel soaked with mixture of: local anesthesia Bupivacaine 0.5% 20 ml (no more than 2 mg/kg) plus lidocaine 2% 10 ml (no more than 3 mg/kg) mixed together, plus epinephrine 5 mcg/ml (max 150 mcg), combined with morphine 0.1 mg/kg (max10 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: normal saline 0.9% to soak the surgicel according to the planned technique
Study: NCT02572297

Intervention type: OTHER
Intervention: video-EEG
Description: Registration of seizures during video-EEG
Study: NCT00992056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol
Description: 5 mg titrated to 10 mg daily versus matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nebivolol
Description: 5 mg titrated to 10 mg daily versus matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol 50 mg titrated to 100 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: Metoprolol 50 mg titrated to 100 mg
Study: NCT00969163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone gel
Description: 300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: testosterone gel
Description: 300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: transdermal placebo gel for 6 weeks
Study: NCT03557957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted correction of plasma sodium levels
Description: Targeted correction of hyponatremia

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care of hyponatremia
Study: NCT04294381

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision tool
Description: participants will be asked to use a decision tool to choose and delineate SMART health behavior goals
Study: NCT00843258

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abduction treatment
Description: Abduction treatment with a Frejka's pillow for 6 weeks
Study: NCT03983720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of degree chronic fatigue.
Description: Evaluation of degree chronic fatigue with the results of survey Fatigue Severity Scale (FSS) and Modified Fatigue Impact Scale (MFIS). This result will allow to divide patients in groups : lowly fatigued and highly fatigued.
Study: NCT02679781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral midazolam
Description: administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
Study: NCT03890900

Intervention type: OTHER
Group type: OTHER
Intervention: T2DXcel mobile application
Description: T2DXcel is a mobile application (patient-facing) that delivers guideline-based diabetes education.
Study: NCT01813201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone undecanoate
Description: Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline isotonic solution
Description: Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
Study: NCT03019523

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine Blend
Description: Taken orally in capsule form

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Taken orally in capsule form
Study: NCT00654225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Study: NCT02679781

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nasal midazolam
Description: administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
Study: NCT05199883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TI.VA algorithm: decision support system
Description: TI.VA algorithm uses BIS and MAP values as control variables to suggest the intervention on propofol and remifentanil levels.
Study: NCT00545467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole
Description: Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.
Study: NCT04077489

Intervention type: PROCEDURE
Group type: OTHER
Intervention: cataract surgery
Description: To measure the MT in congenital cataracts before and after the cataract extraction with IOL implantation surgery